Peer-reviewed veterinary case report
Chemotherapy and surgery for dogs with lymph node histiocytic sarcoma
By Moore, A S et al.·Published in Australian veterinary journal·2017·Veterinary Oncology Consultants, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Chemotherapy for dogs with lymph node metastasis from histiocytic sarcomas.
- Species:
- dog
Plain-English summary
A group of 12 dogs with a type of cancer called histiocytic sarcoma, which had spread to their lymph nodes, were treated with surgery and some received additional chemotherapy. The dogs that got chemotherapy lived significantly longer, with a median survival of about 219 days, compared to just 57 days for those that did not receive chemotherapy. This suggests that adding chemotherapy can help improve survival for dogs with lymph node metastases from this cancer. If your dog has been diagnosed with this condition, discussing chemotherapy options with your vet may be beneficial.
People also search for: dog lymph node cancer treatment · histiocytic sarcoma in dogs · chemotherapy for dog cancer
Abstract
BACKGROUND: Histiocytic sarcomas (HS) frequently metastasise, most commonly to visceral sites, but also to regional lymph nodes. Nodal metastases are associated with a poorer prognosis. This retrospective study aimed to evaluate prognostic factors, including the effect of adjuvant chemotherapy, on survival in dogs with nodal, but not systemic, metastases from HS. METHODS: Retrospective case series of 12 dogs with histologically diagnosed HS metastatic to lymph nodes treated with surgery with and without adjuvant chemotherapy. RESULTS: All dogs had histological evidence of metastasis to lymph nodes, with no clinical evidence for metastasis to viscera. Eight dogs that received chemotherapy had a median estimated survival of 219 days (range 77-1638 days); 1- and 2-year estimated survival rates were 37.7%. Median survival time for 4 dogs with nodal metastases that did not receive chemotherapy was 57 days (range 39-136 days) with none alive 1 year after surgery CONCLUSION: Survival for dogs with only regional nodal metastases from HS appeared to be improved by adjuvant chemotherapy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28124419/